Russia facing shortage of drugs against epilepsy
Russia may be faced with a shortage of Convulex (valproic acid) - one of the most popular drugs for the treatment of epilepsy – as its manufacturer, the Canadian firm Bausch Health, has stopped exports of the drug to the Russian market, reports The Pharma Letter's local correspondent.
According to some Russian media reports, the supplies have become unprofitable for the company after the Russian regulator reduced the maximum price of the drug by 23% to 899.52 roubles ($12). The drug is in the list of vital and essential in Russia, with its maximum price is agreed by the Ministry of Health and the Federal Antimonopoly Service (FAS).
In fact, the Russian pharmaceutical market has been experiencing a shortage of Convulex since late 2021. That has already resulted in the failure of several tenders for its public procurements and there is a high possibility that the current situation will continue to deteriorate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze